What You Need To Know Ahead of Intuitive Surgical's Earnings Release

Sunnyvale, California-based Intuitive Surgical, Inc. (ISRG) develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. Valued at a market cap of $145.6 billion, the company offers the da Vinci Surgical System, which enables minimally invasive surgical procedures, the Ion endoluminal system, and more.

ISRG is expected to release its Q3 2026 earnings after the market closes on Tuesday, October 20. Ahead of this event, analysts anticipate the company will generate earnings of $2.13 per share, representing an increase of 8.7% from $1.96 per share reported in the same quarter last year. The company has surpassed the Street’s bottom-line estimates in each of the past four quarters, which is impressive.   

For fiscal 2026, analysts expect the company to report an EPS of $8.87, indicating a 22.9% rise from $7.22 reported in fiscal 2025. Moreover, its EPS is expected to rise nearly 13% year over year (YoY) to $10.02 in fiscal 2027.   

ISRG stock has declined 8.4% over the past 52 weeks, lagging behind the S&P 500 Index’s ($SPX) 15.2% rise and the State Street Healthcare Select Sector SPDR ETF’s (XLV) 22.2% rise during the same time frame.     

Following the release of its Q2 2026 earnings on July 17, ISRG stock tanked nearly 14.2% as a below-average full-year guidance triggered a wave of Wall Street price cuts. The company’s muted outlook caused a majority of firms to lower the company’s price targets by significant amounts, including Citi, JP Morgan, Mizuho, Bernstein, and others. This loss of investor confidence was mostly caused by the expected deceleration in U.S. procedure growth. The company cited da Vinci procedure growth to track closer to 14.5% this year, at the midpoint of previously provided guidance. This downward adjustment, along with concerns regarding changes to the Affordable Care Act, all contributed to the stock’s decline. 

Despite that, analysts’ consensus opinion on the stock is highly bullish, with a “Strong Buy” rating overall. Among the 31 analysts covering the stock, 22 are recommending a “Strong Buy,” two advise a “Moderate Buy,” six suggest a “Hold,” and the remaining analyst gives a “Strong Sell” for the stock. ISRG’s average analyst price target is $481.93, indicating an upside of 18.5% from the current levels.

On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.